Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA4 | P22748 | 5/20 | 0.49 |
| ▸ | CA7 | P43166 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 5/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830682 | 1.00 | ALDH1A1 (0.50) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL3833359 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL3833355 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL3827526 | 0.83 | HSD11B1 (0.52) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL3827521 | 0.83 | HSD11B1 (0.52) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL3827567 | 0.78 | ALDH1A1 (0.49) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL4207242 | 0.78 | ALDH1A1 (0.49) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL13567975 | 0.75 | ALDH1A1 (0.47) | ALDH1A1TSHRCA1CA2CA4 | |
| SCHEMBL2003440 | 0.73 | ESR1 (0.64) | TSHRCA1CA2CA4CA7 | |
| SCHEMBL1992128 | 0.72 | CA1 (0.61) | TSHRCA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | ALDH1A1 1990/4885TSHR 2591/4885CA1 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.